News and reporting on prostate cancer.
Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
Investigators have applied the platform to isolating viable CTCs in droplets, in which molecular and enzymatic activity can be studied.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.
Noridian GBA has issued the LCD for use of the Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.
Excluding the impact of the one-time sale of patents last year, the company's revenues climbed 38 percent on strong product and service revenue growth.
The company is continuing to collect utility and cost effectiveness data for its SelectMDx test in reducing unnecessary procedures in men with signs of a possible prostate cancer.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.